Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

Panelists discuss how the new nilotinib formulation offers improved convenience by eliminating fasting requirements which may enhance adherence, while emphasizing that clinicians should remain ...

Panelists discuss how innovative approaches to symptom monitoring incorporate multifaceted technology and team-based strategies, including electronic patient-reported outcome tools integrated with ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Video content above is prompted by the following: The Oncology Nursing News program focuses on treatment strategies for ESR1-mutant hormone receptor-positive, HER2-negative breast cancer. Led by ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

The Oncology Nursing News program focuses on treatment strategies for ESR1 -mutant hormone receptor-positive, HER2-negative breast cancer. Led by Tiffany A. Traina, MD, FASCO, from Memorial Sloan ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...